Does the Development of Vaccines Advance Solutions for Tuberculosis?

BACKGROUND: Mycobacterium tuberculosis (Mtb) is considered as one of the most efficacious human pathogens. The global mortality rate of TB stands at approximately 2 million, while about 8 to 10 million active new cases are documented yearly. It is, therefore, a priority to develop vaccines that will...

Full description

Bibliographic Details
Main Authors:	Almatar, Manaf, Makky, Essam A., AlMandeal, Husam, Eker, Emel, Kayar, Begum, Var, Isıl, Koksal, Fatih
Format:	Article
Language:	English
Published:	Bentham Science 2018
Subjects:	QR Microbiology
Online Access:	http://umpir.ump.edu.my/id/eprint/23655/ http://umpir.ump.edu.my/id/eprint/23655/ http://umpir.ump.edu.my/id/eprint/23655/ http://umpir.ump.edu.my/id/eprint/23655/1/Does%20the%20Development%20of%20Vaccines%20Advance%20Solutions%20for%20Tuberculosis.pdf

id	ump-23655
recordtype	eprints
spelling	ump-236552019-01-09T02:57:52Z http://umpir.ump.edu.my/id/eprint/23655/ Does the Development of Vaccines Advance Solutions for Tuberculosis? Almatar, Manaf Makky, Essam A. AlMandeal, Husam Eker, Emel Kayar, Begum Var, Isıl Koksal, Fatih QR Microbiology BACKGROUND: Mycobacterium tuberculosis (Mtb) is considered as one of the most efficacious human pathogens. The global mortality rate of TB stands at approximately 2 million, while about 8 to 10 million active new cases are documented yearly. It is, therefore, a priority to develop vaccines that will prevent active TB. The vaccines currently used for the management of TB can only proffer a certain level of protection against meningitis, TB, and other forms of disseminated TB in children; however, their effectiveness against pulmonary TB varies and cannot provide life-long protective immunity. Based on these reasons, more efforts are channeled towards the development of new TB vaccines. During the development of TB vaccines, a major challenge has always been the lack of diversity in both the antigens contained in TB vaccines and the immune responses of the TB sufferers. Current efforts are channeled on widening both the range of antigens selection and the range of immune response elicited by the vaccines. The past two decades witnessed a signiﬁcant progress in the development of TB vaccines; some of the discovered TB vaccines have recently even completed the third phase (phase III) of clinical trial. OBJECTIVE: The objectives of this article are to discuss the recent progress in the development of new vaccines against TB; to provide an insight on the mechanism of vaccine-mediated specific immune response stimulation; and to debate the interaction between vaccines and global interventions to end TB. Bentham Science 2018-11-26 Article PeerReviewed pdf en http://umpir.ump.edu.my/id/eprint/23655/1/Does%20the%20Development%20of%20Vaccines%20Advance%20Solutions%20for%20Tuberculosis.pdf Almatar, Manaf and Makky, Essam A. and AlMandeal, Husam and Eker, Emel and Kayar, Begum and Var, Isıl and Koksal, Fatih (2018) Does the Development of Vaccines Advance Solutions for Tuberculosis? Current Molecular Pharmacology. ISSN 1874-4702 (In Press) https://doi.org/10.2174/1874467212666181126151948 https://doi.org/10.2174/1874467212666181126151948
repository_type	Digital Repository
institution_category	Local University
institution	Universiti Malaysia Pahang
building	UMP Institutional Repository
collection	Online Access
language	English
topic	QR Microbiology
spellingShingle	QR Microbiology Almatar, Manaf Makky, Essam A. AlMandeal, Husam Eker, Emel Kayar, Begum Var, Isıl Koksal, Fatih Does the Development of Vaccines Advance Solutions for Tuberculosis?
description	BACKGROUND: Mycobacterium tuberculosis (Mtb) is considered as one of the most efficacious human pathogens. The global mortality rate of TB stands at approximately 2 million, while about 8 to 10 million active new cases are documented yearly. It is, therefore, a priority to develop vaccines that will prevent active TB. The vaccines currently used for the management of TB can only proffer a certain level of protection against meningitis, TB, and other forms of disseminated TB in children; however, their effectiveness against pulmonary TB varies and cannot provide life-long protective immunity. Based on these reasons, more efforts are channeled towards the development of new TB vaccines. During the development of TB vaccines, a major challenge has always been the lack of diversity in both the antigens contained in TB vaccines and the immune responses of the TB sufferers. Current efforts are channeled on widening both the range of antigens selection and the range of immune response elicited by the vaccines. The past two decades witnessed a signiﬁcant progress in the development of TB vaccines; some of the discovered TB vaccines have recently even completed the third phase (phase III) of clinical trial. OBJECTIVE: The objectives of this article are to discuss the recent progress in the development of new vaccines against TB; to provide an insight on the mechanism of vaccine-mediated specific immune response stimulation; and to debate the interaction between vaccines and global interventions to end TB.
format	Article
author	Almatar, Manaf Makky, Essam A. AlMandeal, Husam Eker, Emel Kayar, Begum Var, Isıl Koksal, Fatih
author_facet	Almatar, Manaf Makky, Essam A. AlMandeal, Husam Eker, Emel Kayar, Begum Var, Isıl Koksal, Fatih
author_sort	Almatar, Manaf
title	Does the Development of Vaccines Advance Solutions for Tuberculosis?
title_short	Does the Development of Vaccines Advance Solutions for Tuberculosis?
title_full	Does the Development of Vaccines Advance Solutions for Tuberculosis?
title_fullStr	Does the Development of Vaccines Advance Solutions for Tuberculosis?
title_full_unstemmed	Does the Development of Vaccines Advance Solutions for Tuberculosis?
title_sort	does the development of vaccines advance solutions for tuberculosis?
publisher	Bentham Science
publishDate	2018
url	http://umpir.ump.edu.my/id/eprint/23655/ http://umpir.ump.edu.my/id/eprint/23655/ http://umpir.ump.edu.my/id/eprint/23655/ http://umpir.ump.edu.my/id/eprint/23655/1/Does%20the%20Development%20of%20Vaccines%20Advance%20Solutions%20for%20Tuberculosis.pdf
first_indexed	2023-09-18T22:35:32Z
last_indexed	2023-09-18T22:35:32Z
_version_	1777416569968656384

Does the Development of Vaccines Advance Solutions for Tuberculosis?

Similar Items